Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20841001 | 0.97 | TLR8 (0.59) | TLR8TLR7 | |
| SCHEMBL28472239 | 0.84 | TLR8 (0.69) | TLR8TLR7 | |
| SCHEMBL18041313 | 0.84 | TLR8 (0.67) | TLR8TLR7 | |
| SCHEMBL25688112 | 0.84 | TLR8 (0.69) | TLR8TLR7 | |
| SCHEMBL17843455 | 0.83 | TLR8 (0.68) | TLR8TLR7 | |
| SCHEMBL18659723 | 0.83 | TLR8 (0.68) | TLR8TLR7 | |
| SCHEMBL18041391 | 0.81 | TLR8 (0.66) | TLR8TLR7 | |
| SCHEMBL22538803 | 0.81 | TLR8 (0.66) | TLR8TLR7 | |
| SCHEMBL21912241 | 0.81 | TLR8 (0.72) | TLR8TLR7 | |
| SCHEMBL21912982 | 0.81 | TLR8 (0.67) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3949969-A2 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | Silverback Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3595668-B1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS INC (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20210154317-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | ARS Pharmaceuticals, Inc. | 2021-05-27 | — | — | US | disclosed |
| WO-2020056008-A1 | COMPOSITIONS FOR THE TREATMENT OF DISEASE WITH IMMUNE STIMULATORY CONJUGATES | SILVERBACK THERAPEUTICS, INC. (US) | 2020-03-19 | — | — | WO | disclosed |
| WO-2019118884-A1 | ANTIBODY CONSTRUCT-DRUG CONJUGATE FOR THE TREATMENT OF HEPATITIS | SILVERBACK THERAPEUTICS, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
| US-20190169165-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154317-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, FCGR3B, FCGR1A | TLR8 120/4885TLR7 63/4885 |
| US-20190169165-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | TLR8 1/4885TLR7 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.